Recent Progress in Histone Deacetylase (HDAC) 1 Inhibitors as AnticancerAgent
Preeti Patel(Indo Soviet Friendship College of Pharmacy), Vivek Asati(Indo Soviet Friendship College of Pharmacy), Harish Rajak(Guru Ghasidas Vishwavidyalaya), S. Vishakha(Indo Soviet Friendship College of Pharmacy), Simranpreet K. Wahan(Punjab Technical University), Ghanshyam Das Gupta(Indo Soviet Friendship College of Pharmacy), Balak Das Kurmi(Indo Soviet Friendship College of Pharmacy)
Cited by 40
Related Papers
Solid lipid nanoparticles: a review on recent perspectives and patents
|Expert Opinion on Therapeutic Patents|2020|323
Advancement in Solubilization Approaches: A Step towards Bioavailability Enhancement of Poorly Soluble Drugs
|Life|2023|209
A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer
|Drug Delivery and Translational Research|2024|141
Micro- and nanocarrier-mediated lung targeting
|Expert Opinion on Drug Delivery|2010|121
Transdermal Drug Delivery: Opportunities and Challenges for Controlled Delivery of Therapeutic Agents Using Nanocarriers
|Current Drug Metabolism|2017|107